Tal Zaks, Chief Medical Officer, Moderna
Tal oversees preclinical development, clinical development and regulatory affairs across Moderna, a vaccine biotech showing some of the most promising results for a COVID-19 vaccination in development.
Phase III trials for the Moderna COVID-19 vaccine are set to begin at the end of July 2020.
Jacob Glanville PHD , Founding Partner, CEO and President, Distributed Bio
Jacob and his teams apply computationally-guided immunoengineering methods to enable a new generation of monoclonal antibody discovery and universal vaccine design. Jacob is also the inventor of the Centivax universal vaccine technology for influenza, HIV, and other rapidly mutating pathogens
Fun fact: Netflix covered Jacob and his team in their hit documentary ‘Pandemic’
Rino Rappuoli , Chief Scientist & Head of External Research and Development (R&D), GlaxoSmithKline Vaccines
Rino is globally known for his extensive work in vaccines and immunology, and is actively involved in the research and development of vaccines against meningococcal disease, and avian and pandemic influenza.
Rino led the development of the first recombinant bacterial vaccine against pertussis, the adjuvanted influenza vaccines, and the conjugate vaccine against meningococcal-C disease.
Henry Ji , Chairman, President and CEO, Sorrento Therapeutics
Henry co-founded Sorrento Therapeutics in 2006, with an aim to develop therapeutic approaches for cancer. More recently, Sorrento Therapeutics have been active in the COVID-19 space with an antibody cocktail called COVI-SHIELD, and the newly launched I-Cell COVID-19 Cellular Vaccine Program, which is expected to elicit both T cell and B cell immunities against SARS-CoV-2.
Neeta Verma , Director General, National Informatics Center, Government of India
Neeeta has been instrumental in implementing high impact digital initiatives across India, and is involved in the launch and development of the breakthrough contact-tracing app Aarogya Setu, to track COVID-19 movements in India.
The app currently sits at over 100 million downloads, and is one of the most advanced and widely used contact tracing apps to date.
Kate Broderick , Vice President, Research and Development, Inovio Pharmaceuticals
Kate has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA vaccine animal studies and product development in relation to electroporation.
She is also a co-inventor on multiple patents related to DNA vaccine delivery and is principal investigator on grants, awards and contracts from funding bodies such as NIH, Department of Defence and SBIR.
Laura Kahn , Research Scholar, Princeton University , Co-Founder, One Health Initiative
Laura co-founded the One Health Initiative, which seeks to improve the health of all species by increasing communication and collaboration between human, animal and environmental health specialists. She is an expert advisor in the field of zoonosis and has published a number of books on topics surrounding the politics of antimicrobial resistance, one health, and trust in leadership during epidemics.
Fun fact: The 2nd Edition of Laura’s book “Who’s in Charge?: Leadership during Epidemics, Bioterror Attacks, and Other Public Health Crises” was published earlier this year.
Peter Marks , Director, Center for Biologics Evaluation and Research (CBER), FDA
Peter has been with CBER since 2012, becoming Board Director in 2016, is board certified in internal medicine, hematology, medical oncology, and is a Fellow of the American College of Physicians. CBER is responsible for assuring the safety, purity, potency and effectiveness of biologics and related products, such as vaccines and cell therapies.
Lisa Jarvis , Senior Correspondent, C&EN
Lisa tracks big pharma and biotech companies, and specialises in weaving together the business and science between developing drugs, and has reported on important issues such as Ebola, orphan drugs, gender diversity in the drug industry and more recently, COVID-19. Articles to note include “How big pharma firms are quietly collaborating on new coronavirus antivirals” and “The race to pick the best medicines to try against coronavirus”.